BRPI0611409B8 - preparação oral compreendendo lurasidona - Google Patents

preparação oral compreendendo lurasidona

Info

Publication number
BRPI0611409B8
BRPI0611409B8 BRPI0611409A BRPI0611409A BRPI0611409B8 BR PI0611409 B8 BRPI0611409 B8 BR PI0611409B8 BR PI0611409 A BRPI0611409 A BR PI0611409A BR PI0611409 A BRPI0611409 A BR PI0611409A BR PI0611409 B8 BRPI0611409 B8 BR PI0611409B8
Authority
BR
Brazil
Prior art keywords
preparation
lurasidone
water
oral preparation
oral
Prior art date
Application number
BRPI0611409A
Other languages
English (en)
Portuguese (pt)
Inventor
Fujihara Kazuyuki
Original Assignee
Dainippon Sumitomo Pharma Co
Sumitomo Dainippon Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37452103&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0611409(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dainippon Sumitomo Pharma Co, Sumitomo Dainippon Pharma Co Ltd filed Critical Dainippon Sumitomo Pharma Co
Publication of BRPI0611409A2 publication Critical patent/BRPI0611409A2/pt
Publication of BRPI0611409A8 publication Critical patent/BRPI0611409A8/pt
Publication of BRPI0611409B1 publication Critical patent/BRPI0611409B1/pt
Publication of BRPI0611409B8 publication Critical patent/BRPI0611409B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0611409A 2005-05-26 2006-05-26 preparação oral compreendendo lurasidona BRPI0611409B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2005-153508 2005-05-26
JP2005153508 2005-05-26
PCT/JP2006/310571 WO2006126681A1 (ja) 2005-05-26 2006-05-26 医薬品組成物

Publications (4)

Publication Number Publication Date
BRPI0611409A2 BRPI0611409A2 (pt) 2010-11-23
BRPI0611409A8 BRPI0611409A8 (pt) 2015-12-15
BRPI0611409B1 BRPI0611409B1 (pt) 2020-12-29
BRPI0611409B8 true BRPI0611409B8 (pt) 2021-05-25

Family

ID=37452103

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0611409A BRPI0611409B8 (pt) 2005-05-26 2006-05-26 preparação oral compreendendo lurasidona
BR122020005056-0A BR122020005056B1 (pt) 2005-05-26 2006-05-26 Método para preparar uma preparação oral que compreende cloridrato de n-[4-[4-(1,2- benziso-tiazol-3-il)-1-piperazinil]-(2r,3r)-2,3-tetrametileno-butil]-(1r,2s,3r,4s)-2,3-biciclo[2,2,1] heptanodicarboxiimida (lurasidona)

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122020005056-0A BR122020005056B1 (pt) 2005-05-26 2006-05-26 Método para preparar uma preparação oral que compreende cloridrato de n-[4-[4-(1,2- benziso-tiazol-3-il)-1-piperazinil]-(2r,3r)-2,3-tetrametileno-butil]-(1r,2s,3r,4s)-2,3-biciclo[2,2,1] heptanodicarboxiimida (lurasidona)

Country Status (22)

Country Link
US (5) US8729085B2 (cg-RX-API-DMAC7.html)
EP (2) EP1884242B1 (cg-RX-API-DMAC7.html)
JP (2) JP4733120B2 (cg-RX-API-DMAC7.html)
KR (2) KR101380088B1 (cg-RX-API-DMAC7.html)
CN (2) CN102048734B (cg-RX-API-DMAC7.html)
AU (1) AU2006250340C1 (cg-RX-API-DMAC7.html)
BE (1) BE2014C057I2 (cg-RX-API-DMAC7.html)
BR (2) BRPI0611409B8 (cg-RX-API-DMAC7.html)
CA (1) CA2606510C (cg-RX-API-DMAC7.html)
CY (2) CY1114118T1 (cg-RX-API-DMAC7.html)
DK (2) DK1884242T3 (cg-RX-API-DMAC7.html)
ES (2) ES2535478T3 (cg-RX-API-DMAC7.html)
FR (1) FR14C0069I2 (cg-RX-API-DMAC7.html)
HU (1) HUS1400051I1 (cg-RX-API-DMAC7.html)
LU (1) LU92550I2 (cg-RX-API-DMAC7.html)
MX (1) MX2007014872A (cg-RX-API-DMAC7.html)
NL (1) NL300690I2 (cg-RX-API-DMAC7.html)
PL (1) PL1884242T3 (cg-RX-API-DMAC7.html)
PT (1) PT1884242E (cg-RX-API-DMAC7.html)
RU (1) RU2398586C3 (cg-RX-API-DMAC7.html)
SI (1) SI1884242T1 (cg-RX-API-DMAC7.html)
WO (1) WO2006126681A1 (cg-RX-API-DMAC7.html)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006123678A1 (ja) * 2005-05-18 2006-11-23 Dainippon Sumitomo Pharma Co., Ltd. ドロキシドパを含有する安定な錠剤
WO2006126681A1 (ja) * 2005-05-26 2006-11-30 Dainippon Sumitomo Pharma Co., Ltd. 医薬品組成物
US8673353B2 (en) 2008-02-11 2014-03-18 Dainippon Sumitomo Pharma Co., Ltd Tablet having improved elution properties
AU2009258560B2 (en) * 2008-06-13 2014-07-10 Sumitomo Pharma Co., Ltd. Tablet quickly disintegrating in the oral cavity and method for producing the same
JP5694773B2 (ja) * 2008-09-30 2015-04-01 テバ製薬株式会社 圧縮成型製剤およびその製造方法
PE20120654A1 (es) 2009-05-19 2012-05-31 Celgene Corp Formulaciones de 4-amino-2-(2,6-dioxopiperidin-1,3-il) isoindolin-1,3-diona
JP5893616B2 (ja) 2010-10-18 2016-03-23 大日本住友製薬株式会社 注射用徐放性製剤
WO2012063246A1 (en) * 2010-11-11 2012-05-18 Mapi Pharma Ltd. Amorphous form of lurasidone hydrochloride
WO2012107890A2 (en) * 2011-02-10 2012-08-16 Ranbaxy Laboratories Limited Crystalline forms of lurasidone hydrochloride
WO2012156981A1 (en) 2011-05-13 2012-11-22 Cadila Healthcare Limited Pharmaceutical compositions of lurasidone
EP2736905A4 (en) 2011-07-28 2015-07-29 Mapi Pharma Ltd INTERMEDIATE COMPOUNDS AND PROCESS FOR THE PREPARATION OF LURASIDONE AND SALTS THEREOF
CN102911169B (zh) * 2011-08-02 2015-05-06 上海医药工业研究院 一种卢拉西酮的制备方法
US20140243383A1 (en) 2011-08-24 2014-08-28 Cadila Healthcare Limited Pharmaceutical compositions of silodosin
CN103446071B (zh) * 2012-05-29 2017-12-19 江苏豪森药业集团有限公司 一种口服片剂及其制备方法和用途
CN102688210A (zh) * 2012-06-21 2012-09-26 李兴惠 鲁拉西酮的药物组合物和制备方法
CN102688209A (zh) * 2012-06-21 2012-09-26 李兴惠 鲁拉西酮片和制备方法
CN106074414B (zh) * 2012-07-12 2019-01-18 成都康弘药业集团股份有限公司 一种含有鲁拉西酮的口腔崩解片及其制备方法
CN103006661B (zh) * 2012-12-06 2015-02-18 江苏先声药物研究有限公司 一种含有盐酸鲁拉西酮的制剂及其制备方法
US20150157628A1 (en) * 2013-12-11 2015-06-11 Saravanan Kannusamy Pharmaceutical compositions of Lurasidone and Process for preparation thereof
WO2016012898A1 (en) * 2014-07-25 2016-01-28 Lupin Limited Oral pharmaceutical composition of lurasidone
CN104606133A (zh) * 2015-01-07 2015-05-13 万特制药(海南)有限公司 鲁拉西酮口服混悬液及其制备方法
WO2016139683A2 (en) * 2015-03-05 2016-09-09 Jubilant Generics Limited Pharmaceutical compositions of lurasidone and process for preparing the same
DE102016205950A1 (de) * 2016-04-08 2017-10-12 Dietrich Seidel Mittel zur Verwendung bei entzündlichen Zuständen der Schleimhäute
EA201991007A1 (ru) * 2016-11-02 2019-08-30 Сановель Илач Санайи Ве Тиджарет А.Ш. Твердые фармацевтические композиции на основе гидрохлорида луразидона для перорального применения
CN108567758A (zh) * 2017-03-08 2018-09-25 湖南洞庭药业股份有限公司 盐酸鲁拉西酮片剂及其制备方法
CN111698992A (zh) * 2017-08-18 2020-09-22 艾伯维公司 用于治疗子宫内膜异位症、子宫肌瘤、多囊卵巢综合症或子宫腺肌症的药物配制物
CN107875122A (zh) * 2017-12-17 2018-04-06 佛山市弘泰药物研发有限公司 一种盐酸鲁拉西酮自微乳制剂及其制备方法
CN107854445A (zh) * 2017-12-17 2018-03-30 佛山市弘泰药物研发有限公司 一种盐酸鲁拉西酮分散片及其制备方法
CN107854446A (zh) * 2017-12-19 2018-03-30 佛山市弘泰药物研发有限公司 一种盐酸鲁拉西酮口崩片及其制备方法
WO2019167978A1 (ja) 2018-02-28 2019-09-06 大日本住友製薬株式会社 溶出が制御された水性懸濁型医薬製剤
EP3772992B1 (de) 2018-04-10 2022-05-18 Freshfoodz GmbH Verfahren zur konservierung einer warmzubereiteten speise und zum bereitstellen von gemeinschaftsverpflegung
WO2019199134A1 (ko) * 2018-04-13 2019-10-17 주식회사 삼양바이오팜 레날리도마이드를 포함하는 약제학적 조성물
CA3153004A1 (en) * 2019-09-25 2021-04-01 Nobelpharma Co., Ltd. Granule having masked unpleasant taste and method for producing same
WO2022042646A1 (zh) * 2020-08-26 2022-03-03 浙江华海药业股份有限公司 盐酸鲁拉西酮组合物及其制备方法
AT17300U3 (de) * 2020-12-03 2022-02-15 G L Pharma Gmbh Feste orale pharmazeutische Zusammensetzung
US20240100022A1 (en) * 2020-12-23 2024-03-28 Sumitomo Pharma Co., Ltd. Oral solid preparation

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4600579A (en) * 1983-06-07 1986-07-15 Mallinckrodt, Inc. N-acetyl-p-aminophenol compositions containing partially gelatinized starch and method for preparing same
US4551177A (en) 1984-04-23 1985-11-05 National Starch And Chemical Corporation Compressible starches as binders for tablets or capsules
US4609675A (en) 1984-08-17 1986-09-02 The Upjohn Company Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing
US4837031A (en) 1987-09-17 1989-06-06 Mallinckrodt, Inc. Compositions containing ibuprofen
US5047246A (en) 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
US5104648A (en) 1989-02-02 1992-04-14 Mallinckrodt Specialty Chemicals Company High ibuprofen content granulations
US4911921A (en) 1989-02-02 1990-03-27 Mallinckrodt, Inc. High ibuprofen content granulations
JP2800953B2 (ja) * 1990-07-06 1998-09-21 住友製薬株式会社 新規なイミド誘導体
US5605889A (en) 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
PT812195E (pt) 1995-02-28 2003-03-31 Aventis Pharma Inc Composicao farmaceutica para compostos de piperidinoalcanol
JP4022269B2 (ja) 1995-05-26 2007-12-12 協和醗酵工業株式会社 医薬組成物
PL191533B1 (pl) 1997-10-20 2006-06-30 Dainippon Sumitomo Pharma Co Szybko-rozpuszczalna kompozycja farmaceutyczna
JP4063386B2 (ja) 1998-01-29 2008-03-19 キッセイ薬品工業株式会社 速放性経口医薬品組成物
US6150366A (en) 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations
PL198797B1 (pl) * 1999-03-31 2008-07-31 Janssen Pharmaceutica Nv Zastosowanie wstępnie żelowanej skrobi
US6586617B1 (en) 1999-04-28 2003-07-01 Sumitomo Chemical Takeda Agro Company, Limited Sulfonamide derivatives
AU2001246861A1 (en) * 2000-04-10 2001-10-23 Sumitomo Pharmaceuticals Co. Ltd. Sustained release preparations
AU2001286237A1 (en) * 2000-09-22 2002-04-02 Sumitomo Pharmaceuticals Company, Limited Oral preparations with favorable disintegration characteristics
DE60236418D1 (de) 2001-03-19 2010-07-01 Dainippon Sumitomo Pharma Co Arylsubstituierte alicyclische verbindung und diese enthaltende medizinische zusammensetzung
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
EP1944030B1 (en) * 2002-08-22 2018-08-01 Sumitomo Dainippon Pharma Co., Ltd. Agent for treatment of schizophrenia
CA2494707A1 (en) 2002-08-30 2005-01-06 Pharmacia Corporation Pharmaceutical solid dosage forms exhibiting reproductible drug release profile
JPWO2004078173A1 (ja) * 2003-02-05 2006-06-08 塩野義製薬株式会社 溶出性の改善された錠剤
AU2004279318C1 (en) 2003-09-12 2020-06-25 Amgen Inc. Rapid dissolution formulation of a calcium receptor-active compound
CN1913876B (zh) 2003-12-09 2013-06-26 大日本住友制药株式会社 含药物的颗粒和包含这种颗粒的固体制剂
WO2006096439A2 (en) 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
WO2006126681A1 (ja) 2005-05-26 2006-11-30 Dainippon Sumitomo Pharma Co., Ltd. 医薬品組成物

Also Published As

Publication number Publication date
AU2006250340C1 (en) 2014-06-12
AU2006250340B2 (en) 2012-02-09
CA2606510A1 (en) 2006-11-30
LU92550I2 (fr) 2015-11-02
JP4733120B2 (ja) 2011-07-27
FR14C0069I2 (fr) 2015-11-20
BRPI0611409B1 (pt) 2020-12-29
KR101380088B1 (ko) 2014-04-10
US8883794B2 (en) 2014-11-11
PT1884242E (pt) 2013-05-21
CN101184489A (zh) 2008-05-21
US20180161322A1 (en) 2018-06-14
PL1884242T3 (pl) 2013-09-30
HK1108379A1 (en) 2008-05-09
CN102048734A (zh) 2011-05-11
BE2014C057I2 (cg-RX-API-DMAC7.html) 2025-12-10
SI1884242T1 (sl) 2013-07-31
RU2007148997A (ru) 2009-07-10
US20150056284A1 (en) 2015-02-26
FR14C0069I1 (fr) 2014-10-24
KR20130122019A (ko) 2013-11-06
US8729085B2 (en) 2014-05-20
JP2011126915A (ja) 2011-06-30
JP5285105B2 (ja) 2013-09-11
MX2007014872A (es) 2008-02-15
BRPI0611409A8 (pt) 2015-12-15
CN102048734B (zh) 2013-11-20
BR122020005056A8 (pt) 2022-11-22
US20140235651A1 (en) 2014-08-21
EP1884242A1 (en) 2008-02-06
KR101552033B1 (ko) 2015-09-09
US20090143404A1 (en) 2009-06-04
JPWO2006126681A1 (ja) 2008-12-25
ES2535478T3 (es) 2015-05-12
DK1884242T3 (da) 2013-05-06
BR122020005056B1 (pt) 2023-01-10
US9907794B2 (en) 2018-03-06
RU2398586C3 (ru) 2017-10-04
EP2422783B1 (en) 2015-04-08
NL300690I2 (nl) 2017-11-02
BRPI0611409A2 (pt) 2010-11-23
CA2606510C (en) 2014-07-22
DK2422783T3 (en) 2015-05-11
EP2422783A1 (en) 2012-02-29
EP1884242A4 (en) 2009-07-01
KR20080012306A (ko) 2008-02-11
AU2006250340A1 (en) 2006-11-30
CY2014039I1 (el) 2016-06-22
CY2014039I2 (el) 2016-06-22
BR122020005056A2 (cg-RX-API-DMAC7.html) 2010-11-23
US9555027B2 (en) 2017-01-31
WO2006126681A1 (ja) 2006-11-30
CN101184489B (zh) 2011-01-19
RU2398586C2 (ru) 2010-09-10
HUS1400051I1 (hu) 2016-10-28
US20150265611A1 (en) 2015-09-24
CY1114118T1 (el) 2016-06-22
ES2408687T3 (es) 2013-06-21
EP1884242B1 (en) 2013-04-17

Similar Documents

Publication Publication Date Title
BRPI0611409B8 (pt) preparação oral compreendendo lurasidona
RU2424240C2 (ru) Антибактериальные производные пиперидина
RU2458920C2 (ru) Новые соединения
ATE419848T1 (de) Cycloalkyl-lactam-derivate als inhibitoren von 11-beta-hydroxysteroiddehydrogenase 1
MY141794A (en) Benzamide and heteroarene derivatives
DE602005018758D1 (de) Am histamin-h3-rezeptor wirksame mittel, herstellung und therapeutische anwendungen
BRPI0407097A (pt) Antagonista do casr
BRPI0517803A (pt) pirazolpirimidinas 1,4-substituìdas como inibidores de cinase
TNSN08405A1 (en) Cyclohexylpyrazole - lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
DK2021336T3 (da) 11-beta-hydroxysteroid-dehydrogenase-1-inhibitorer
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
JP2008110984A5 (cg-RX-API-DMAC7.html)
TNSN01005A1 (en) GLYBURIDE COMPOSITION
ATE397605T1 (de) Nebivolol und dessen pharmazeutisch unbedenkliche salze, herstellungsverfahren und pharmazeutische zusammensetzungen von nebivolol
EA200971086A1 (ru) Фармацевтические композиции и способ лечения шизофрении
BRPI0417833A (pt) novos derivados de benzofurano, os quais podem ser usados na profilaxia ou tratamento de distúrbios relacionados com o receptor 5-ht6
MA28706B1 (fr) Antagoniste des recepteurs du glucagon, preparation et utilisations therapeutiques
EA200971087A1 (ru) Фармацевтические композиции и способ лечения острой мании
BR112022020609A2 (pt) Composição farmacêutica para administração oral que compreende derivado de aminopirimidina ou sal, hidrato ou solvato farmaceuticamente aceitável do mesmo
BRPI0513891B8 (pt) derivados de propenil piperazina substituídos, seu uso como novos inibidores de histona deacetilase, composição farmacêutica, combinação e processo de preparação destes
PE20060771A1 (es) Profarmaco de amida de gemcitabina y composiciones que lo contienen
BRPI0411603A (pt) 4-(aminometil)-piperidina benzamidas como antagonistas 5ht4
BRPI0511466B8 (pt) agonistas peptídicos do receptor de vasopressina, composição farmacêutica compreendendo os referidos agonistas e uso destes
MX2009011416A (es) Tia(di)azoles como antagonistas del receptor de dopamina 2 de disociacion rapida.
ATE495159T1 (de) Diaminocyclohexan- und diaminocyclopentanderivate

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: SUMITOMO DAINIPPON PHARMA CO., LTD. (JP)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09X Republication of the decision to grant [chapter 9.1.3 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/12/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/05/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B17A Notification of administrative nullity (patentee has 60 days time to reply to this notification)

Free format text: REQUERENTE DA NULIDADE: THALITA DUQUE MARTINS PAES - 870210057587 - 25/06/2021

B25D Requested change of name of applicant approved

Owner name: SUMITOMO PHARMA CO., LTD. (JP)

B25G Requested change of headquarter approved

Owner name: SUMITOMO PHARMA CO., LTD. (JP)